CA2374141A1 - Therapie genique toxique a base d'osteonectine destinee au traitement de tumeurs et de tissus calcifies - Google Patents

Therapie genique toxique a base d'osteonectine destinee au traitement de tumeurs et de tissus calcifies Download PDF

Info

Publication number
CA2374141A1
CA2374141A1 CA002374141A CA2374141A CA2374141A1 CA 2374141 A1 CA2374141 A1 CA 2374141A1 CA 002374141 A CA002374141 A CA 002374141A CA 2374141 A CA2374141 A CA 2374141A CA 2374141 A1 CA2374141 A1 CA 2374141A1
Authority
CA
Canada
Prior art keywords
osn
gene
cells
therapeutic
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002374141A
Other languages
English (en)
Inventor
Leland W. K. Chung
Chia-Ling Hsieh
Kenneth S. Koeneman
Fan Yeung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UVA Licensing and Ventures Group
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2374141A1 publication Critical patent/CA2374141A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des promoteurs, des activateurs et d'autres éléments régulateurs qui régulent l'expression dans des cellules de tumeurs et de tissus possédant un potentiel de calcification. L'invention concerne spécifiquement des vecteurs d'expression, des cellules hôtes et des animaux transgéniques comportant une séquence régulatrice de l'ostéonectine (OSN).
CA002374141A 1999-05-28 2000-05-25 Therapie genique toxique a base d'osteonectine destinee au traitement de tumeurs et de tissus calcifies Abandoned CA2374141A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13644099P 1999-05-28 1999-05-28
US60/136,440 1999-05-28
PCT/US2000/014482 WO2000072679A1 (fr) 1999-05-28 2000-05-25 Therapie genique toxique a base d'osteonectine destinee au traitement de tumeurs et de tissus calcifies

Publications (1)

Publication Number Publication Date
CA2374141A1 true CA2374141A1 (fr) 2000-12-07

Family

ID=22472869

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002374141A Abandoned CA2374141A1 (fr) 1999-05-28 2000-05-25 Therapie genique toxique a base d'osteonectine destinee au traitement de tumeurs et de tissus calcifies

Country Status (6)

Country Link
EP (1) EP1182929A4 (fr)
JP (1) JP2003500422A (fr)
AU (1) AU5291800A (fr)
CA (1) CA2374141A1 (fr)
IL (1) IL146794A0 (fr)
WO (1) WO2000072679A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030118585A1 (en) 2001-10-17 2003-06-26 Agy Therapeutics Use of protein biomolecular targets in the treatment and visualization of brain tumors
EP1308517A1 (fr) * 2001-10-31 2003-05-07 Aventis Pharmacueticals Products Inc. Vecteurs pour l'expression de multiples transgenes
CA2802143C (fr) 2003-01-14 2018-06-19 Dana-Farber Cancer Institute Polynucleotide codant un sparc comme agent sensibilisant de therapie du cancer
JP2007524393A (ja) 2003-06-24 2007-08-30 ザ ジョンズ ホプキンス ユニバーシティ 癌を検出するためのメチル化遺伝子バイオマーカー
AU2006249235B2 (en) 2004-05-14 2010-11-11 Abraxis Bioscience, Llc Sparc and methods of use thereof
US8420603B2 (en) 2004-05-14 2013-04-16 Abraxis Bioscience, Llc SPARC and methods of use thereof
AR053246A1 (es) * 2006-04-28 2007-04-25 Fundacion Inst Leloir Un fragmento aislado de adn del promotor humano de sparc y su uso para dirigir la expresion de un gen heterologo en celulas tumorales
WO2016036960A1 (fr) 2014-09-03 2016-03-10 Genesegues, Inc. Nanoparticules thérapeutiques et compositions, procédés et systèmes associés
CN114533959B (zh) * 2022-04-02 2022-12-09 山东隽秀生物科技股份有限公司 一种肌腱修复材料、制备方法及在制备肌腱修复产品中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5416017A (en) * 1990-05-18 1995-05-16 The Scripps Research Institute Cholera toxin gene regulated by tissue-specific promoters
AU5333298A (en) * 1996-12-27 1998-07-31 Instituto De Investigaciones Bioquimicas Fundacion Campomar Compositions and methods for tumour therapy
US5772993A (en) * 1997-01-21 1998-06-30 The University Of Virginia Patent Foundation Osteocalcin promoter-based toxic gene therapy for the treatment of calcified tumors and tissues

Also Published As

Publication number Publication date
IL146794A0 (en) 2002-07-25
EP1182929A4 (fr) 2003-04-16
JP2003500422A (ja) 2003-01-07
AU5291800A (en) 2000-12-18
EP1182929A1 (fr) 2002-03-06
WO2000072679A1 (fr) 2000-12-07

Similar Documents

Publication Publication Date Title
JP5153031B2 (ja) 腫瘍特異的細胞傷害性を誘導するための方法および組成物
KR20220097414A (ko) X-연관 연소 망막층간분리 치료법을 위한 crispr 및 aav 전략
CA2374141A1 (fr) Therapie genique toxique a base d'osteonectine destinee au traitement de tumeurs et de tissus calcifies
KR20120132594A (ko) 마이크로ｒｎａ를 이용한 조절을 통한 암 특이적 유전자 치료제
Tsuruta et al. Combination effect of adenovirus-mediated pro-apoptotic bax gene transfer with cisplatin or paclitaxel treatment in ovarian cancer cell lines
AU769773B2 (en) Bone sialoprotein based toxic gene therapy for the treatment of calcified tumors and tissues
JP2002543792A (ja) ベクターによるトランスポゾン配列の供給及び組込み
EP0999278A1 (fr) Eléments de régulation de spécificité vasculaire de la région d'encadrement 5' du gène de la desmine
US20030213006A1 (en) Beta-hcg promoter based tumor restrictive gene expression for cancer theraphy
EP1594549B1 (fr) Plasmide vegf inductible par l'hypoxie utile pour traiter une maladie ischemique
EP1287362A2 (fr) Compositions et methodes destinees a la modulation de l'expression specifique des tumeurs
WO2001090344A1 (fr) $g(b)-hcg promoter based tumor-restrictive gene expression for cancer gene therapy
WO2000024254A1 (fr) Compositions et procedes pour moduler l'expression a l'interieur des cellules de muscles lisses
US20040038232A1 (en) Compositions and methods for modulating tumor specific expression
US6825035B1 (en) Compositions and methods for modulating expression within smooth muscle cells
US20030078224A1 (en) Gene expression directed by a super-PSA promoter
JP2003521895A (ja) スーパーｐｓａプロモーターにより指令された遺伝子発現
CA2403795A1 (fr) Replication d'adenovirus sous controle de promoteur d'osteocalcine, utilisee a des fins therapeutiques
EP1360191A2 (fr) Procedes et compositions pour l'expression de polynucleotides specifiquement dans des cellules de muscle lisse in vivo
US20040101840A1 (en) Identification, cloning and characterization of a novel pc-1 gene differentially expressed in prostate cells and tissues
WO2003006621A2 (fr) Super agent promoteur de l'osteocalcine pour traiter les tumeurs calcifiees et les tissus calcifies
WO2001081547A2 (fr) Identification, clonage et caracterisation d'un nouveau gene pc-1 exprime differemment dans des cellules et des tissus de la prostate

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20060525